Friday, 2 May 2014

Deca Durabolin Abuse - Recommended Dose Of Deca Durabolin

http://www.iroids.com/decca-durabol-250
An anabolic androgenic steroid that was originally developed to treat wasting diseases, Deca Durabolin or Nandrolone Decanoate is a performance enhancing drug used by male and female bodybuilders to experience dramatic changes in performance and ability to handle intense workouts.


This Schedule III drug has an active life of 14-16 days and is detectable over a period of 16-18 months. Deca Durabolin has the molecular weight of 428.65 g/mol at the base and its molecular formula is C28H44O3. Deca has the anabolic/androgenic ratio of 125:37 and the chemical name of 19-nor-androst-4-en-3-one-17beta-ol.

The ideal dose of Deca Durabolin for men is doses of 2mg per pound of body weight or 250–500mg per week though some men may administer Deca in low doses at 200mg per week or as high as 400mg per week. Female athletes, on the other hand, generally use this steroid in doses of 50 to 150mg per week.

Deca Durabolin Abuse-Recommended Dose Of Deca Durabolin
Deca is not advised to patients with debilitating health conditions such as breast cancer with high calcium levels, severe kidney impairment, prostate cancer, and hypersensitivity. This steroid should not be used by women who are pregnant, breastfeeding, or keen to get pregnant while using this steroid. While using this steroid, athletes and others should regularly monitor liver function and blood cholesterol. Overdosing of this steroid should always be avoided as it may lead to chills, sleeplessness, skin pigmentation, decreased sexual drive, nausea, and diarrhea. Deca Durabolin abuse may also result in increased level of calcium in blood when overdosed by female users.


Deca Durabolin overdosing can even lead to testicular atrophy, gynecomastia (including lactation in rare cases), and sexual dysfunction. Long-term abuse of this drug can result in withdrawal of ovarian action, elevated blood pressure, shrinking of the testicles, bone age advancement, atrophy of the breasts, early epiphyseal closure, hypercalcaemia, hypercalciuria, suppression of ovarian activity, edema, and depression.

No comments:

Post a Comment